This page looks plain and unstyled because you're using a non-standard compliant browser. To see it in its best form, please upgrade to a browser that supports web standards. It's free and painless.
kilomentor | 25 October, 2009 17:32
Kilomentor tries to keep up with opinions expressed concerning chemical process development. Girish Malhotra recently wrote an article, Less is More in API Process Development published electronically at PharmaManufacturing.com. He asked the question, Why does U.S. pharmaceutical industry persist in using complex manufacturing processes to make active pharmaceutical ingredients? He cites as examples US6037483, US6245913, US6867306, US6835848 and US6331638. Am I missing something? None of these applications is from the laboratory of an American company. The authors are without exception Indians either working in India or in one case working in Ireland.
I would dispute many of the contentions made in the article; for example, I think the priorities of innovative manufacturing chemists and generic manufacturing chemists may explain an enormous part of the differences he tries to assert. However, with such examples, I think a discussion need go no further.
Aroma Chemicals | 26/10/2009, 00:38
| « | January 2010 | » | ||||
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| 31 | ||||||
Surely a debate is needed on those lines! Good job.. Go ahead.